Michael Maris, MD
Hematology & Oncology · Denver, CONPI 1053395624
Payments from drug & device makers
Across 283 payments — averaging $5797.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$561K
- Trillium Therapeutics USA, LLC$285K
- AstraZeneca$224K
- Gilead$179K
- Genentech, Inc.$178K
- Macrogenics, Inc.$90K
- plus $125K from 27 others
Across 3 payments — averaging $15,626 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$45K
- Pfizer$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 35 | $560,640 |
| Trillium Therapeutics USA, LLC | 23 | $284,763 |
| AstraZeneca | 4 | $224,047 |
| Gilead(2 entities) | 65 | $178,502 |
| Genentech, Inc. | 28 | $177,997 |
| Macrogenics, Inc. | 27 | $90,188 |
| Celularity Inc. | 3 | $77,725 |
| Verastem, Inc. | 29 | $37,742 |
| Astrazeneca UK Limited | 1 | $7,500 |
| AbbVie | 18 | $409 |
| Mesoblast, Inc. | 3 | $204 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $156 |
| Incyte Corporation | 3 | $104 |
| Astellas Pharma US Inc | 3 | $69 |
| Rigel Pharmaceuticals, Inc. | 1 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Johnson & Johnson | 3 | $55 |
| Genentech USA, Inc. | 3 | $50 |
| Novartis | 3 | $46 |
| Legend Biotech USA Inc. | 2 | $46 |
| Amgen | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Agios Pharmaceuticals, Inc. | 2 | $33 |
| Autolus Inc | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Sanofi | 1 | $22 |
| Pfizer | 1 | $18 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Merck | 1 | $14 |
How this compares
$1,640,693 in reported general payments places this provider in the 80th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Denver
- Allen CohnDenver$13.5M
- Robert RifkinDenver$11.3M
- Henning SchadeDenver$9M
- Jeffrey MatousDenver$8.4M
- Peter ForsbergDenver$5.5M
- Tara GregoryDenver$3.5M
- Mabel MardonesDenver$3M
- Amy SchmidtDenver$2.8M
- Michael TeesDenver$2.7M
- Yousuf GaffarDenver$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.